目的總結結腸冗長癥合并結直腸癌的臨床病理特征，并文獻復習結腸冗長癥與結直腸癌的關系。 方法回顧性分析蘭州大學第一醫院普外一科2011年1月至2012年12月期間收治的17例結腸冗長癥合并結直腸癌患者的臨床資料。 結果184例結直腸癌患者中合并結腸冗長癥17例（9.24%），合并家族性息肉病惡變2例（1.09%），合并遺傳性非息肉病性結直腸癌1例（0.54%），合并炎癥性腸病1例（0.54%）。合并結腸冗長癥的比例較高（P＜0.05）。其中術前經結腸氣鋇灌腸檢查診斷為結腸冗長癥5例，術中診斷為結腸冗長癥12例。所有患者均行手術治療，切除結腸13～80 cm，平均33.8 cm。術后發生肺部感染、切口液化1例，腹水1例，腸瘺1例，骶前感染1例。術后17例患者均獲隨訪，隨訪時間6～12個月，中位數為10個月。隨訪期間，1例患者于術后1年出現卵巢轉移。 結論結腸冗長癥合并頑固性便秘可能是結直腸癌發病的高危因素。
Objective To systematically assess the efficacy and clinical significance of antibiotic prophylaxis in severe acute pancreatitis (SAP), so as to provide references for its rational clinical application. Methods For collecting the randomized controlled trials (RCTs) about antibiotic prophylaxis in SAP, a search was conducted in MEDLINE, EMbase, Cochrane Central Register of Controlled Trials, CBM and CNKI from the date of their establishment to August, 2010. After the clinical studies meeting the inclusive criteria were extracted and their quality was assessed. Meta-analysis was conduced by using RevMan 5.0 software. Results Twelve RCTs were included with a total of 777 patients. The results of Meta-analysis showed compared with the control group, the antibiotic prophylaxis group was not associated with a statistically signi?cant reduction in mortality (RR=0.75, 95%CI 0.50 to 1.12), in the incidence of infected pancreatic necrosis (RR 0.82, 95%CI 0.63 to 1.09), in surgical interventions (RR=0.97, 95%CI 0.74 to 1.26), and in the incidence of nonpancreatic infections (RR=0.73, 95%CI 0.48 to 1.10). Conclusion Antibiotic prophylaxis for SAP does not reduce mortality, infected necrosis, or surgical intervention.
Objective To evaluate the efficacy and safety of intraoperative mesenchymal chemotherapy with 5-FU implants in radical gastrectomy of advanced gastric cancer. Methods From January 2008 to September 2009， 102 patients with historically proven advanced gastric cancer were enrolled in our department and were allocated to undergo either radical gastrectomy and intraoperative mesenchymal chemotherapy with 5-FU implants 800 mg（treatment group， n=51）， or radical gastrectomy alone （control group， n=51）. The postoperative complications and recurrence rate between two groups were compared. Results There were no significant differences on the volume of abdominal cavity drainage， count of white blood cells， albumin level， and gastrointestinal adverse events between the two groups （P＞0.05）. After a median follow-up of 28 months， the local recurrence rate was lower among patients in treatment group than that in control group （16.3% vs. 39.1%， P＜0.05）， the survival rate of 3-year was higher in treatment group than that in control group （85.8% vs. 67.3%， P＜0.05）. Conclusions Compared with the control group， there are no significant adverse reactions on patients with advanced gastric cancer who were implanted fluorouraci1 implants during operation， which can reduce local recurrence rates and improve the survival rates.